Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Next Previous
X
Search
Trial Profile

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BEGIN: SWITCH 2; SWITCH 2
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 28 Oct 2019 Results evaluating the IHSG level 2 definition by applying it to a series of clinical trials in patients with type 1 or type 2 diabetes published in the Diabetes Care
    • 05 Oct 2018 Results of a post hoc analysis from SWITCH 1 and 2 trials presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 02 Oct 2018 Results of post hoc analysis from SWITCH 1 and 2 trials presented in a Novo Nordisk media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top